Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized phase II trial of nal-IRI + 5-fluorouracil vs 5-fluorouracil in gemcitabine-pretreated cholangio- and gallbladder carcinoma
2016-003709-33Phase 2Completed
- Sponsor
- AIO-Studien
- Start
- Jan 2017
- Modality
- Small Molecules, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, randomised trial of nanoliposomal irinotecan in cholangiocarcinoma (CCA) and gallbladder cancer (2 arms), sponsored by AIO-Studien. Primary endpoint: Progression-free survival. Started Jan 2017; status: completed.
02
Drugs
nanoliposomal irinotecan
03
Conditions
cholangiocarcinoma (CCA)gallbladder cancer
Beyond the preview
Go deeper on 2016-003709-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-003709-33.